Evidence map›Paper›PMID 27477823›Full record

ArticleEpidemiology and infection2016

Epidemiological impact of a syphilis vaccine: a simulation study.

D Champredon, C E Cameron, M Smieja, J Dushoff

Open access · hybridAbstract read
In one paragraph

Article in Epidemiology and infection, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Notes on syphilis vaccine development.Frontiers in immunology · 2022
    Review
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

D ChampredonSchool of Computational Science and Engineering,McMaster University,Hamilton,Ontario,Canada.ORCID 0000-0002-7090-8757
C E CameronDepartment of Biochemistry and Microbiology,University of Victoria,Victoria,British Columbia,Canada.
M SmiejaDepartment of Pathology and Molecular Medicine,McMaster University,Hamilton,Ontario,Canada.
J DushoffDepartment of Theoretical Biology,McMaster University,Hamilton,Ontario,Canada.
McMaster University · CAUniversity of Victoria · CA

Funding

Extracellular Matrix Adhesins of Treponema pallidumR01AI051334 · NIAID · UNIVERSITY OF WASHINGTON · PI CAMERON, CAROLINE E · 2002 to 2017
$3.4M
Extracellular Matrix Adhesins of Treponema pallidumR37AI051334 · NIAID · UNIVERSITY OF VICTORIA · PI CAROLINE E CAMERON · 2019 to 2026
$2.3M
NIAID NIH HHS R01 AI051334NIAID NIH HHS R37 AI051334
6 · The paper itself

Abstract

Despite the availability of inexpensive antimicrobial treatment, syphilis remains prevalent worldwide, affecting millions of individuals. Furthermore, syphilis infection is suspected of increasing both susceptibility to, and tendency to transmit, HIV. Development of a syphilis vaccine would be a potentially promising step towards control, but the value of dedicating resources to vaccine development should be evaluated in the context of the anticipated benefits. Here, we use a detailed mathematical model to explore the potential impact of rolling out a hypothetical syphilis vaccine on morbidity from both syphilis and HIV and compare it to the impact of expanded 'screen and treat' programmes using existing treatments. Our results suggest that an efficacious vaccine has the potential to sharply reduce syphilis prevalence under a wide range of scenarios, while expanded treatment interventions are likely to be substantially less effective. Our modelled interventions in our simulated study populations are expected to have little effect on HIV, and in some scenarios lead to small increases in HIV incidence, suggesting that interventions against syphilis should be accompanied with interventions against other sexually transmitted infections to prevent the possibility that lower morbidity or lower perceived risk from syphilis could lead to increases in other sexually transmitted diseases.

Indexed as

Models, TheoreticalVaccinationAdolescentAdultAgedBacterial VaccinesComputer SimulationFemaleHeterosexualityHIV InfectionsHumansIncidenceInfectious Disease Transmission, VerticalMaleMiddle AgedPrevalenceBacterial VaccinesCo-infectionHIVimmunizationmathematical modellingpublic healthsyphilis

Identifiers

PMID27477823
PMCPMC5080673
OpenAlexW2501940400

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.